- Home
- STCN vs INTS Comparison
STCN vs INTS Comparison
Compare STCN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- INTS
- Stock Information
- Founded
- STCN 1986
- INTS 2012
- Country
- STCN United States
- INTS United States
- Employees
- STCN N/A
- INTS N/A
- Industry
- STCN Advertising
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- STCN Consumer Discretionary
- INTS Health Care
- Exchange
- STCN Nasdaq
- INTS Nasdaq
- Market Cap
- STCN 75.0M
- INTS 64.9M
- IPO Year
- STCN 1994
- INTS 2023
- Fundamental
- Price
- STCN $10.57
- INTS $3.75
- Analyst Decision
- STCN
- INTS Buy
- Analyst Count
- STCN 0
- INTS 1
- Target Price
- STCN N/A
- INTS $12.00
- AVG Volume (30 Days)
- STCN 11.6K
- INTS 12.5K
- Earning Date
- STCN 11-06-2024
- INTS 11-11-2024
- Dividend Yield
- STCN N/A
- INTS N/A
- EPS Growth
- STCN 203.29
- INTS N/A
- EPS
- STCN 3.17
- INTS N/A
- Revenue
- STCN $169,044,000.00
- INTS N/A
- Revenue This Year
- STCN N/A
- INTS N/A
- Revenue Next Year
- STCN N/A
- INTS N/A
- P/E Ratio
- STCN $3.34
- INTS N/A
- Revenue Growth
- STCN N/A
- INTS N/A
- 52 Week Low
- STCN $7.36
- INTS $2.01
- 52 Week High
- STCN $13.00
- INTS $11.44
- Technical
- Relative Strength Index (RSI)
- STCN 41.19
- INTS 41.20
- Support Level
- STCN $10.54
- INTS $3.51
- Resistance Level
- STCN $11.12
- INTS $3.99
- Average True Range (ATR)
- STCN 0.41
- INTS 0.29
- MACD
- STCN 0.00
- INTS -0.01
- Stochastic Oscillator
- STCN 60.98
- INTS 36.38
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.